Compare iShares MSCI Malaysia ETF (EWM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Malaysia ETF vs TG Therapeutics Inc — how do they compare? iShares MSCI Malaysia ETF trades at $26.66 (market cap $256.41M), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 31.8× iShares MSCI Malaysia ETF's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, iShares MSCI Malaysia ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Malaysia ETF for 66 Days and TG Therapeutics Inc for 16 Days on average.
| EWM | TGTX | |
|---|---|---|
Market Cap | $256.41M | $8.16B |
Volume | 111,962 | 1,735,121 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.42 | $59.06 |
52-Week Low | $25.33 | $26.94 |
Typical Hold Time | 66 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWM stock trades at $26.66 with minimal daily movement (+0.19%). Technical indicators show conflicting signals with moving averages suggesting bearish pressure while oscillators indicate potential oversold conditions. The stock faces immediate resistance at $27 and support at $26. Recent news highlights regional environmental challenges affecting operations.
The stock presents a cautious outlook with mixed technical signals and limited fundamental data available. Near-term direction will depend on earnings results and management guidance. Key risks include operational disruptions from regional environmental issues and broader market volatility affecting small-cap stocks.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Malaysia ETF
EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
